Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-squamous Non-small Cell Lung Cancer With EGFR Mutation: a Multicentre, Multi-cohort, Exploratory Study.

NCT05962021 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT05962021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05962021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-squamous Non-small Cell Lung Cancer With EGFR Mutation: a Multicentre, Multi-cohort, Exploratory Study.
Lead sponsor
Peking University People's Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2023
Completion date
June 30, 2026
Enrollment
126 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

egfr positive non-small cell lung cancer, non squamous non small cell lung cancer